HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody

HFB30132A possesses differentiated properties providing strong potential for COVID-19 treatment and prevention HONG KONG--(BUSINESS WIRE)--HiFiBiO Therapeutics, a multinational biotechnology company with unique expertise in immune modulation and singl...

Full "IntellAsia: Resources" article